Á lódáil...
“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”
BACKGROUND: Glivec (imatinib mesylate), produced by the pharmaceutical company Novartis, is prescribed in the case of Chronic Myeloid Leukemia, one of the most common blood cancers in eastern countries. After more than a decade of legal battles surrounding its patentability, the Supreme Court of Ind...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
BioMed Central
2014
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3884017/ https://ncbi.nlm.nih.gov/pubmed/24393270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1744-8603-10-3 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|